Surveillance Strategy for Patients With BCLC Stage B Hepatocellular Carcinoma After Achieving Complete Remission: Data From the Real World

Ying Wu, Lujun Shen, Han Qi, Fei Cao, Shuanggang Chen, Lin Xie, Tao Huang, Danyang Zhou, Jinqing Mo, and Weijun Fan

Objective: There is a lack of consensus on the surveillance strategy for Barcelona Clinic liver cancer (BCLC) stage B hepatocellular carcinoma (HCC) patients with complete remission (CR). We performed a real-world, retrospective analysis of the surveillance strategy for BCLC stage B HCC patients after radical therapy with CR to support clinical decision-making.

Materials and Methods: We analyzed 546 BCLC stage B HCC patients with CR after radical treatments (surgery/ablation) at Sun Yat-sen University Cancer Center from January 2007 to December 2019. The intensity of surveillance interval was defined as the mean of surveillance interval within 2 years. The primary endpoint of the study was overall survival (OS) and extra-Milan criteria relapse.

Results: During a median follow-up time of 23.9 months (range = 3.1–148.3 months), there were 11.9% of patients died, 56.6% of patients developed recurrence, the vast majority of patients experienced recurrence within 2 years, and 27.8% patients developed extra-Milan criteria recurrence. The median disease-free survival and OS were 33.6 and 60.0 months, respectively. Patients were divided into regular surveillance group (RS) (≤4.3 months) and irregular surveillance (IRS) group (>4.3 months) based on the optimal cutoff value of the intensity of surveillance interval. The RS group owned a lower incident of extra-Milan criteria relapse and smaller and fewer tumors at recurrence than IRS group, which contributed to the prolonged OS. Besides, the cutoff values of surveillance interval that could lead to significant differences in the incidence of extra-Milan criteria relapse during 0–6, 6–12, and 12–18 months after CR were 2.6, 2.9, and 3 months, respectively.

Conclusions: The average surveillance interval for patients with BCLC stage B HCC achieved CR should not exceed 4.3 months during the first 2 years’ follow-up. During three different phases of the initial 18 months after CR, individualized surveillance showed intervals no more than 3 months were required to reduce the incidence of extra-Milan criteria relapse.

Keywords: hepatocellular carcinoma, BCLC stage B, surveillance interval, complete remission, extra-Milan criteria relapse
INTRODUCTION

Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the fourth leading cause of cancer death worldwide in 2018 (1). Rates of both incidence and mortality are two to three times higher among men in most regions (1). Hepatitis B virus (HBV) and hepatitis C virus (HCV) are considered to be the main pathogens for the development of HCC, especially in Asia (2). Recently, the number of patients with HCC originating from HCV has increased year by year, and the number of HCC patients owing to HBV has decreased (3).

The Barcelona Clinic liver cancer (BCLC) stage B (intermediate stage) (4) patients account for ~19.4% of total HCC (5). Also, the BCLC stage B represents a heterogeneous group of patients (6), which were more complicated and experience relapses earlier than BCLC stage A. The main factors were the span of liver function score (Child–Pugh: 5–9), the difference of tumor size (diameter 3–10 cm or more), tumor number (2–20 or more), and the difference of tumor distribution (single lobe limited or double lobe diffused).

Untreated patients at BCLC stage B present a median survival of 16 months or a survival rate of 49% at 2 years (7, 8). Chemoembolization extends the survival of these patients to a median of up to 19–20 months (8, 9). Surgery and ablation comprise potentially curative treatment modalities for BCLC stage B HCC patients (10). Besides, patients in this stage achieving downstaging from combined treatments or TACE (transarterial chemoembolization) can be suitable for radical treatments (6, 11). Unfortunately, the median survival of BCLC stage B HCC patients after curative treatment was 45 months (12). Tumor recurrence after curative surgery occurs in 50–70% of patients, which constitutes either intrahepatic metastases (often within 2 years after surgery) or a new HCC in the remaining cirrhotic liver (10, 13). Factors of early or late recurrence or/and metastases were complex, including tumor size and history of rupture, etc. (11, 14, 15).

Patients with recurrence after radical therapies may still be candidates for curative therapies (10, 16, 17). Early diagnosis of recurrence is more likely to receive curative treatment and achieve better disease control and prolonged survival (18). Although recent guidelines recommend surveillance strategies (10, 19) for patients after curative treatment, there is a lack of specific consensus on surveillance regimen after curative treatment of HCC, especially for BCLC stage B HCC patients with complete remission (CR) after radical treatment. For HCC patients with BCLC stage B, whether the current surveillance strategies are sufficient remains unclear. Moreover, although patients are recommended for surveillance according to the guidelines in the clinic, in the real world, for various reasons, patients cannot fully follow the guidelines for surveillance strategies. Therefore, the impact of irregular surveillance (IRS) in the real world on patient survival is also unclear.

Based on this background, we performed a real-world, retrospective analysis of the surveillance strategy for BCLC stage B HCC patients after radical therapy with CR to support clinical decision-making.

MATERIALS AND METHODS

Patients

This study met the requirements of the Declaration of Helsinki and was approved by the Institutional Review Board of Sun Yat-sen University Cancer Center. We retrospectively analyzed BCLC stage B HCC patients who underwent radical therapy (surgery/ablation) from an institutional database at Sun Yat-sen University Cancer Center, from January 2007 to December 2019. A total of 2,193 consecutive patients were initially considered eligible. All cases were diagnosed as HCC according to pathology or clinical criteria (10, 19). This study included BCLC stage B HCC patients who received radical treatment (surgery/ablation) and achieved CR. Multidetector computed tomography (CT) and/or magnetic resonance imaging (MRI) were performed routinely to evaluate the local or distant extension of the primary tumors. Patients who visited our hospital at least 3 months after radical treatment were candidates for this study. CR is defined as no recurrence within 3 months after radical treatments. Patients were also excluded if they met any of the following criteria: age <18 or >75 years, non-HCC, mixed liver cancer, non-BCLC stage B, non-radical treatment, non-CR, died of postoperative complications. After excluding 1,637 patients according to the exclusion criteria, 546 patients were finally included in the study. All patients received radical treatment, including surgery and ablation. Some patients were treated with TACE before having undergone radical treatment, whereas others received a one-stage radical treatment.

Surveillance Strategy

After radical operation, patients were informed to perform multiphasic, high-quality, cross-sectional imaging of the chest, abdomen, and pelvis every 3–6 months for 2 years and then followed up every 6–12 months as recommended by the guideline (19). Recurrence was defined as radiological evidence of intra-abdominal or abdominal soft tissue around the surgical site, or else distant metastasis. Besides, the date of each surveillance was recorded, and the end point of the surveillance was the time of tumor extra-Milan criteria recurrence and death. Intensity of surveillance interval was defined as the mean of surveillance interval within 2 years. For patients who died, survival time after curative treatment and the result of death were recorded.

Statistical Analysis

Overall survival (OS) and extra-Milan criteria recurrence were measured from the date of CR to death or extra-Milan criteria recurrence or last follow-up evaluation. Continuous variables were presented as mean ± standard deviation and analyzed using the Student t-test. Categorical variables were analyzed using the \( \chi^2 \) or Fisher exact test, as appropriate. Survival rates were

Abbreviations: HCC, hepatocellular carcinoma; CR, complete remission; BCLC, Barcelona Clinic Liver Cancer; RS, regular surveillance; IRS, irregular surveillance; HBV, hepatitis B virus; HCV, hepatitis C virus; DFS, disease-free survival; OS, overall survival; TACE, transarterial chemoembolization; CT, multidetector computed tomography; MRI, magnetic resonance imaging; AFP, α-fetoprotein; HR, hazard ratio; CI, confidence interval.
estimated by the Kaplan–Meier (K-M) method. Differences in OS were assessed for significance using the log-rank test. The Cox proportional hazards regression model was used to determine the factors associated with survival. As per initial design, all variables with a $P < 0.05$ by univariable analysis were entered in the multivariable analysis. Finally, only one variable was found to be associated with survival, and multivariable analysis could not be performed. Optimal cutoff for analysis was selected using X-Tile. Statistical analyses were performed using SPSS 18 for Windows (SPSS Inc., Chicago, IL, USA). Pictures were drawn using GraphPad Prism version 6.0 and R-3.6.3 software. All $P$-values were two-sided, and $P < 0.05$ was considered significant.

RESULTS

Clinical and Pathological Characteristics of All HCC Patients

We enrolled 546 BCLC stage B HCC patients who achieved CR after radical treatment. The clinical and pathological characteristics of all the 546 patients are listed in Table 1. The 546 patients were followed 2,115 times, with an average of 4 times per person over 2 years. According to the best cutoff, regular surveillance group (RS) ($n = 441$) was defined as receipt of repeated CT/MRI with mean interval $\leq$ 4.3 months within 2 years. The IRS group ($n = 105$) was defined as receipt of repeated CT/MRI with mean interval $> 4.3$ months within 2 years. Overall demographics were similar, but RS patients with a higher proportion of poor differentiation ($P < 0.001$).

Follow-Up and Assessment of Prognosis of All HCC Patients

Median follow-up time was 23.9 months (range = 3.1–148.3 months), and the median disease-free survival (DFS) and OS were 33.6 and 60.0 months, respectively; 11.9% of patients (65/546) died, with a 2-years OS rate of 88.0%, and the 5-years OS rate was 87.0%; 56.6% of patients (309/546) developed a recurrence, with 2-years DFS rate of 53.0% and 5-years DFS rate of 46.0% (Figures 1A,B). The 1-, 3-, and 5-years survival rates

| Variable | RS ($n = 441$) | IRS ($n = 105$) | $P$ |
|----------|----------------|----------------|-----|
| Gender | Male | 87.5 | 386 | 89.5 | 94 | 0.573 |
| | Female | 12.5 | 55 | 11.5 | 11 |
| Age (years) | $\leq$ 41 | 18.8 | 83 | 11.4 | 12 | 0.073 |
| | $> 41$ | 81.2 | 358 | 88.6 | 93 |
| HBV or HCV | No | 12.9 | 57 | 16.2 | 17 | 0.380 |
| | Yes | 87.1 | 384 | 83.8 | 88 |
| Cirrhosis | No | 34.7 | 153 | 34.3 | 36 | 0.937 |
| | Yes | 65.3 | 288 | 65.7 | 69 |
| AFP ($\mu g/L$) | $\leq$ 400 | 53.1 | 234 | 59.0 | 62 | 0.359 |
| | $> 400$ | 46.9 | 207 | 41.0 | 43 |
| Tumor size (mm) | $\leq$ 40 | 38.1 | 168 | 37.1 | 39 | 0.857 |
| | $> 40$ | 61.9 | 273 | 62.9 | 66 |
| Multinodular tumor ($\geq 4$) | No | 82.5 | 364 | 89.5 | 94 | 0.080 |
| | Yes | 17.5 | 77 | 10.5 | 11 |
| One-stage radical treatment | No | 56.5 | 249 | 60.0 | 63 | 0.419 |
| | Yes | 43.5 | 192 | 40.0 | 42 |
| Therapeutic modalities | Surgery | 78.9 | 348 | 83.8 | 88 | 0.261 |
| | Ablation | 21.1 | 93 | 16.2 | 17 |
| Differentiation | Well | 4.2 | 15 | 13.2 | 12 | 0.001 |
| | Moderated | 53.1 | 188 | 60.4 | 55 |
| | Poor | 42.7 | 151 | 26.4 | 24 |
| Satellite nodules | No | 90.0 | 316 | 93.4 | 85 | 0.319 |
| | Yes | 10.0 | 35 | 6.6 | 6 |
| Venous invasion | No | 67.2 | 236 | 73.6 | 67 | 0.240 |
| | Yes | 32.8 | 115 | 26.4 | 24 |
| Perineural invasion | No | 99.7 | 350 | 97.8 | 89 | 0.109 |
| | Yes | 0.3 | 1 | 2.2 | 2 |

The meaning of the bold values provided was $p < 0.05$.  

TABLE 1 | Correlation between surveillance interval and clinicopathological characteristics in HCC patients.
FIGURE 1 | The DFS and OS curves with 95% CIs and risk tables and the recurrence patterns for HCC patients. (A) The DFS of 546 patients. The 2- and 5-years DFS rates were 53.0 and 46.0%; (B) the OS of 546 patients. The 2- and 5-years OS rates were 88.0 and 87.0%, respectively; (C) the probability density plot of recurrence showed that relapse cases centered in the first 2 years after curative treatment; (D) the hazard rate of recurrence curve showed that the recurrence hazard peaked during the first 2 years after curative treatment.

FIGURE 2 | In the RS group, significantly prolonged OS in BCLC stage B HCC patients with CR after radical treatment, but there was no difference between the two groups in terms of the extra-Milan criteria relapse. (A) Kaplan–Meier curve for OS of HCC patients stratified by surveillance interval; (B) Kaplan–Meier curve for extra-Milan criteria relapse of HCC patients stratified by surveillance interval.

were 99, 97, and 91% in the RS group, and 96, 79, and 72% in the IRS group. Besides, 27.8% of patients (152/546) developed extra-Milan criteria recurrence. In patients with recurrence, the IRS group owned a higher ratio of extra-Milan criteria recurrence than the RS group ($P = 0.004$), 64.6 and 44.7%, respectively. After recurrence, 75% of patients received further treatment, including
radical resection (41.5%), local treatment (55.0%), and systemic treatment (3.5%).

From the DFS curve and the probability density plot, we found that 90.0% of patients experienced recurrence within 1 year, and 97.0% of patients experienced recurrence within 2 years (Figures 1A,C). Moreover, the hazard of relapse reached its peak in the first 2 years (Figure 1D). Thus, it makes sense to focus on surveillance during the first 2-years after curative treatments to detect early recurrence at a potentially more treatable stage.

Univariate and Multivariate Analyses of Prognostic Factors for Recurrence and Survival of All HCC Patients

The result of univariate analysis revealed that surveillance interval \( P = 0.005, \) HR = 1.981, 95% confidence interval (CI) = 1.227–3.198 (Figure 2A) was prognostic factors for OS, but not for extra-Milan criteria relapse \( (P = 0.860, \) HR = 0.968, 95% CI = 0.677–1.385) (Figure 2B). Besides, age \( (P = 0.013, \) HR = 0.498, 95% CI = 0.288–0.863), tumor size \( (P = 0.019, \) HR = 1.952, 95% CI = 1.163–3.414), and differentiation \( (P = 0.044, \) HR = 1.552, 95% CI = 1.011–2.381) were prognostic factors for OS (Table 2).

In addition, univariate analysis revealed that age \( (P = 0.006, \) HR = 0.583, 95% CI = 0.398–0.854) was a prognostic factor only for extra-Milan criteria relapse (Table 3).

Multivariate analysis demonstrated that surveillance interval \( (P = 0.037, \) HR = 1.798, 95% CI = 1.037–3.117), age \( (P = 0.008, \) HR = 0.456, 95% CI = 0.256–0.811), and tumor size \( (P = 0.018, \) HR = 2.379, 95% CI = 1.160–4.876) were independent risk factors for OS (Table 2).

Univariate and Multivariate Analyses of Prognostic Factors for Survival of HCC Patients With Relapse

To further assess the association between surveillance interval and survival, further analysis was performed on relapsed patients.

The correlation analysis demonstrated that patients in the IRS group owned a higher incidence of extra-Milan criteria recurrence \( (P = 0.004, \) a larger size of the recurrent tumor \( (P = 0.011, \) and a higher proportion of multinodular tumors \( (P = 0.003) \) (Table 4) and less likely to receive secondary treatments after recurrence \( (P = 0.001). \) Moreover, the violin plot also

### Table 3: Cox proportional hazard regression analysis of patients’ extra-Milan criteria relapse.

| Variable                                      | Univariable |          |          | Multivariable |          |
|-----------------------------------------------|-------------|----------|----------|---------------|----------|
| HR (95% CI)                                   | P           | HR (95% CI) | P          |
| Gender (male/female)                          | 1.248 (0.787–1.978) | 0.346    |
| Age (years) \( \leq 41/ > 41\)               | 0.583 (0.398–0.854) | 0.006    |
| HBV or HCV (no/yes)                          | 0.899 (0.579–1.386) | 0.592    |
| Cirrhosis (no/yes)                           | 1.326 (0.119–1.326) | 0.119    |
| AFP (µg/L) \( <400/ >400\)                  | 0.767 (0.555–1.061) | 0.109    |
| Tumor size (mm) \( <40/ >40\)               | 1.167 (0.839–1.632) | 0.359    |
| Multinodular tumor (no/yes)                  | 1.418 (0.956–2.104) | 0.083    |
| One-stage radical treatment (no/yes)         | 1.115 (0.809–1.538) | 0.506    |
| Therapeutic modalities (surgery/ablation)     | 0.764 (0.494–1.181) | 0.226    |
| Differentiation (well/moderated/poor)         | 0.987 (0.738–1.320) | 0.928    |
| Satellite nodules (no/yes)                   | 1.524 (0.879–2.643) | 0.134    |
| Venous invasion (no/yes)                     | 1.166 (0.812–1.674) | 0.406    |
| Perineural invasion (no/yes)                 | 0.899 (0.126–6.432) | 0.916    |
| Surveillance interval (RS/IRS)               | 0.968 (0.677–1.385) | 0.860    |

The meaning of the bold values provided was \( p < 0.05. \)

### Table 2: Cox proportional hazard regression analysis of patients’ overall survival.

| Variable                                      | Univariable |          |          | Multivariable |          |
|-----------------------------------------------|-------------|----------|----------|---------------|----------|
| HR (95% CI)                                   | P           | HR (95% CI) | P          |
| Gender (male/female)                          | 1.239 (0.592–2.589) | 0.570    |
| Age (years) \( \leq 41/ > 41\)               | 0.498 (0.288–0.863) | 0.013    |
| HBV or HCV (no/yes)                          | 2.150 (0.865–5.3346) | 0.099    |
| Cirrhosis (no/yes)                           | 1.288 (0.759–2.185) | 0.348    |
| AFP (µg/L) \( <400/ >400\)                  | 1.212 (0.736–1.943) | 0.426    |
| Tumor size (mm) \( <40/ >40\)               | 1.952 (1.116–3.414) | 0.019    |
| Multinodular tumor (no/yes)                  | 1.653 (0.966–2.829) | 0.067    |
| One-stage radical treatment (no/yes)         | 1.381 (0.861–2.215) | 0.180    |
| Therapeutic modalities (surgery/ablation)     | 0.822 (0.441–1.531) | 0.536    |
| Differentiation (well/moderated/poor)         | 1.552 (1.011–2.381) | 0.044    |
| Satellite nodules (no/yes)                   | 1.644 (0.744–3.632) | 0.219    |
| Venous invasion (no/yes)                     | 0.972 (0.530–1.786) | 0.928    |
| Perineural invasion (no/yes)                 | 2.623 (0.363–18.981) | 0.339    |
| Surveillance interval (RS/IRS)               | 1.981 (1.227–3.198) | 0.005    |

The meaning of the bold values provided was \( p < 0.05. \)
TABLE 4 | Correlation between surveillance interval and clinicopathological characteristics with relapsed HCC patients.

| Variable                        | RS (n = 244) | IRS (n = 65) | P     |
|---------------------------------|-------------|-------------|-------|
|                                 | %  | No. | %  | No. |       |
| Extra-Milan criteria relapse    | No | 56.3 | 135 | 35.4 | 23 | 0.004 |
|                                 | Yes| 44.7 | 109 | 64.6 | 42 |       |
| AFP (µg/L)                      | ≤400 | 63.5 | 155 | 56.9 | 37 | 0.330 |
|                                 | >400 | 36.5 | 89  | 43.1 | 28 |       |
| Relapse location                | Local | 86.1 | 210 | 80.0 | 52 | 0.226 |
|                                 | Distant | 13.9 | 34  | 20.0 | 13 |       |
| Size of recurrent tumor (mm)    | ≤30 | 85.7 | 209 | 72.3 | 47 | 0.011 |
|                                 | >30 | 14.3 | 35  | 27.7 | 18 |       |
| Multinodular recurrence         | No | 79.5 | 192 | 61.5 | 39 | 0.003 |
|                                 | Yes| 20.5 | 55  | 38.5 | 26 |       |
| Secondary treatment             | No | 20.6 | 50  | 41.5 | 27 | 0.001 |
|                                 | Yes| 79.4 | 193 | 58.5 | 38 |       |

The meaning of the bold values provided was p < 0.05.

FIGURE 3 | The violin plot indicated that the RS group and the IRS group had significant difference in size of recurrent tumor (P = 0.007).

indicated that the IRS group owned a larger size of the recurrent tumor (Figure 3).

Besides, univariate analysis also revealed surveillance interval (P = 0.002, HR = 2.160, 95% CI = 1.338–3.488) (Figure 5A), extra-Milan criteria relapse (P < 0.001, HR = 2.638, 95% CI = 1.597–4.358) (Figure 4A), size of recurrent tumor (P < 0.001, HR = 2.758, 95% CI = 1.661–4.579) (Figure 4B), multinodular recurrence (P < 0.001, HR = 4.682, 95% CI = 2.903–7.552) (Figure 4C), and secondary treatment (P < 0.001, HR = 0.261, 95% CI = 0.155–0.439) (Figure 4D) were prognostic factors for OS in relapsed patients (Table 5). Multivariate analysis demonstrated that extra-Milan criteria relapse (P = 0.038, HR = 1.782, 95% CI = 1.032–3.077) and secondary treatment (P < 0.001, HR = 0.335, 95% CI = 0.193–0.581) were independent risk factors for OS (Table 5).

Comparison of Surveillance Interval and 0–18 Months Extra-Milan Criteria Relapse of All HCC Patients

According to the hazard rate curve that the recurrence risk of BCLC stage B patients with CR was still high at 0–24 months (Figure 1D). Moreover, although the K-M curve showed no difference between the RS and IRS groups for extra-Milan criteria
Relapse in HCC patients (Figure 2B) and HCC patients relapse (Figure 5B), the interval between 0 and 18 months of surveillance also appeared to be associated with extra-Milan criteria relapse (Figure 5B). In the further analysis of patients with extra-Milan criteria relapse in 0–18 months, we found that the RS group could earlier detect extra-Milan criteria relapse ($P = 0.046$, HR = 0.602, 95% CI = 0.366–0.991) (Figure 6B), which significantly prolonged OS ($P < 0.001$, HR = 2.893, 95% CI = 1.647–5.082) (Figure 6A). Based on this, we further analyzed the surveillance interval of 0–6, 6–12, 12–18, and 18–24 months.

We found that patients with an average surveillance interval ≤2.6 months within 0–6 months could earlier detect extra-Milan criteria relapse ($P = 0.042$, HR = 0.713, 95% CI = 0.515–0.988) (Figure 7A). In addition, patients with an average...
TABLE 5 | Cox proportional hazard regression analysis of relapsed patients’ overall survival.

| Variable                                      | Univariable | Multivariable |
|-----------------------------------------------|-------------|---------------|
|                                               | HR (95% CI) | P             | HR (95% CI) | P      |
| Extra-Milan criteria relapse (no/yes)         | 2.638 (1.597–4.358) | <0.001     | 1.782 (1.032–3.077) | 0.038  |
| AFP (µg/L) (≤400/>400)                        | 0.912 (0.562–1.480) | 0.710      |               |        |
| Relapse location (local/distant)              | 1.055 (0.688–1.618) | 0.805      |               |        |
| Size of recurrent tumor (mm) (≤30/>30)        | 2.758 (1.661–4.579) | <0.001     |               |        |
| Multinodular recurrence (no/yes)             | 4.682 (2.903–7.552) | <0.001     |               |        |
| Secondary treatment (no/yes)                 | 0.261 (0.155–0.439) | <0.001     | 0.335 (0.193–0.581) | <0.001 |
| Surveillance interval (RS/IRS)               | 2.160 (1.338–3.488) | 0.002      | 1.309 (0.777–2.207) | 0.312  |

The meaning of the bold values provided was \( p < 0.05 \).

![Figure 6](image_url) In the RS group, extra-Milan criteria recurrence was detected earlier and significantly prolonged OS in 0–18 months relapsed HCC patients. (A) Kaplan–Meier curve for OS of 0–18 months relapsed HCC patients stratified by surveillance interval; (B) Kaplan–Meier curve for extra-Milan criteria recurrence of 0–18 months relapsed HCC patients stratified by surveillance interval.

DISCUSSION

Currently, the European Society for Medical Oncology proposes that follow-up of patients who underwent radical treatments (resection or ablation) should consist of the clinical evaluation of liver decompensation and the early detection of recurrence by dynamic CT or MRI studies every 3 months during the 1st year and surveillance every 6 months thereafter (10). But the National Comprehensive Cancer Network offers a different view, recommending continuous surveillance every 3–6 months, for 2 years, and then every 6–12 months (19). However, these two guidelines are quite different in terms of the surveillance interval, not for specific patients. Also, the guidelines do not specifically recommend surveillance intervals for BCLC stage B HCC patients with CR, which were more complicated and had relapses earlier than those of BCLC stage A. Although patients are recommended for surveillance according to clinical guidelines, in the real world, for a variety of reasons, patients cannot fully follow the guidelines for surveillance strategies. Therefore, the impact of IRS in the real world on patient survival is unclear.

Previous studies have indicated that earlier identification of disease may facilitate patient eligibility for investigational studies or other forms of treatment (19, 20). HY K et al. demonstrated that the detection of small HCC eligible for curative treatment is increased by frequent surveillance (16, 18). Besides, patients in the RS group were diagnosed at earlier stages than the IRS or non-surveillance groups, which had more chance for curative treatments (18). Moreover, AA M et al. also reported that a long surveillance interval compromises OS in high-risk patients who underwent curative thermal ablation for HCC within the Milan criteria (21). Besides, other tumors have the same results for which more intensive surveillance after surgery for esophageal adenocarcinoma, colorectal...
cancer, and non–small cell lung cancer translates into improved survival (22–25). Although there is no high-level evidence, the cutoff of 2 years has been adopted to grossly classify early and late recurrences (14, 26). In our result, we also found that the vast majority of patients experienced recurrence within 2 years. Other than that, we also proved that RS owned a lower incidence of extra-Milan criteria relapse and smaller and fewer tumors at recurrence than those of IRS group, which contributed to the prolonged OS. Thereby, the average surveillance interval for patients with BCLC stage B HCC who achieved CR should not exceed 4.3 months during the first 2 years’ follow-up.

Over the past 20 years, the Milan criteria have been highly successful in selecting patients for good long-term survival and remain the criteria for potential transplant candidates for HCC (27). It is important to identify the possible predictive factors of within and extra-Milan criteria recurrences after radical treatments (28). Early diagnosis of extra-Milan criteria recurrence can enable patients to receive a more timely intervention after recurrence and control the development of tumors. In our study, we also found that the RS group could earlier detect extra-Milan criteria relapse and significantly prolonged OS in 0–18 months relapsed patients. Moreover, during 0–6, 6–12, and 12–18 months of the initial 18 months after CR, individualized surveillance intervals that no more than 3 months were required to reduce the incidence of extra-Milan criteria relapse. The interval of surveillance according to current guidelines is therefore insufficient, especially 12–18 months after CR.

As mentioned above, despite this study having many clinical implications, we should be clear that it is a retrospective study with its limitations. First, our study was conducted in a single center. The collection of multicenter data to expand the sample size is the next step that needs to be done. Moreover, the follow-up strategy of patients in different stages after radical operation needs to be further explored. Finally, RS could detect tumor recurrence at an early stage and prolong the survival of patients, which requires further clinical trials to verify it.

In conclusion, our results demonstrated that the surveillance interval for BCLC stage B HCC patients with CR after curative treatment should not exceed 4.3 months during the first 2 years’ follow-up. Besides, during 0–6, 6–12, and 12–18 months of the initial 18 months after CR, individualized surveillance intervals of no more than 3 months were required to reduce the incidence of extra-Milan criteria relapse.
DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Institutional Review Board of Sun Yat-sen University Cancer Center. Written informed consent to participate in this study was provided by the participants or their legal guardian/next of kin.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424. doi: 10.3322/caac.21492
2. Kekule AS, Lauer U, Meyer M, Caselmann WH, Hosf Schneider PH, Koshy R. The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature. (1990) 343:457–61. doi: 10.1038/343457a0
3. Sasaki Y, Yamada T, Tanaka H, Ohigashi H, Eguchi H, Yano M, et al. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma. Ann Surg. (2006) 244:771–80. doi: 10.1097/01.slta.0000225126.56483.b3
4. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. (1999) 19:329–38. doi: 10.1055/s-2007-1007122
5. Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Park MS, et al. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1,717 treatment-naïve patients with hepatocellular carcinoma. Liver Int. (2012) 32:1120–7. doi: 10.1111/j.1478-3231.2012.02811.x
6. Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. (2019) 156:65. doi: 10.1053/j.gastro.2018.08.065
7. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. (2010) 51:1274–83. doi: 10.1002/heap.23485
8. Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg. (2011) 98:1210–24. doi: 10.1002/bjs.7669
9. Zhao J, Zhang S, Liu Y, He X, Qu M, Xu G, et al. Single-cell RNA sequencing reveals the heterogeneity of liver-resident immune cells in human. Cell Discov. (2020) 6:22. doi: 10.1038/s41421-020-0157-z
10. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2019) 30:871–3. doi: 10.1093/annonc/mdy510
11. Vogel A, Saborowski A. Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma. Cancer Treat Rev. (2020) 82:101946. doi: 10.1016/j.ctrv.2019.101946
12. Pecorelli A, Lenzi B, Gramenzi A, Garuti F, Farinati F, Giannini EG, et al. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. Liver Int. (2017) 37:423–33. doi: 10.1111/liv.13242
13. Gentile D, Donadon M, Lleo A, Agheoni A, Roncalli M, di Tommaso L, et al. Surgical treatment of hepatocelangiocarcinoma: a systematic review. Liver Cancer. (2020) 9:15–27. doi: 10.1111/1758-3841.13079
14. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. (2003) 38:280–7. doi: 10.1016/S0168-8278(02)03064-4
15. Lee K-F, Chong CCN, Fong AKW, Fung AKY, Lok H-T, Cheung Y-S, et al. Pattern of disease recurrence and its implications for postoperative surveillance after curative hepatectomy for hepatocellular carcinoma: experience from a single center. Hepatol Res. (2018) 17:320–30. doi: 10.1111/hepr.12737
16. Trinhet I-C, Chaffaut C, Bouvier V, Degos F, Henrion J, Fontaine H, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-months periodicities. Hepatology. (2011) 54:1987–97. doi: 10.1002/hep.24545
17. Lee DD, Sapisochin G, Mehta N, Gorgen A, Musto KR, Hajda H, et al. Surveillance for HCC after Liver transplantation: increased monitoring may yield aggressive treatment options and improved postrecurrence survival. Transplantation. (2020) 140:2105–12. doi: 10.1097/TP.0000000000003137
18. Kim HY, Nam JY, Lee IJ, Lee HA, Chang Y, Lee HY, et al. Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area. Alimentary Pharmacol Therapeut. (2018) 47:1490–501. doi: 10.1111/apj.14623
19. Benson AB, D’Angelica MI, Bennett DE, Abrams SR, Anaya DA, et al. Guidelines insights: hepatobiliary cancers, version 2.2019. J Natl Comprehensive Cancer Netw. (2019) 17:302–10. doi: 10.6004/jnccn.2019.0019
20. Madkhali AA, Fadel ZT, Aljiffry MM, Hassainan MM. Surgical treatment for hepatocellular carcinoma. Saudi J Gastroenterol. (2015) 21:11–7. doi: 10.4103/1319-3767.151216
21. Liu W, Zheng Y, Zou R, Shen J, He W, Yang Z, et al. Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation. BMC Cancer. (2018) 18:1186. doi: 10.1186/s12885-018-5069-z
22. Sandler RS, Nyren O, Ekborn A, Eisen GM, Yuen J, Josefsson S. The risk of esophageal cancer in patients with achalasia. A population-based study. JAMA. (1995) 274:1359–62. doi: 10.1001/jama.1995.0353017039029
23. Backhus LM, Farjah F, Liang C-KJ, He H, Varghese TK, Au DH, et al. Imaging surveillance and survival for surgically resected non-small-cell lung cancer. J Surg Res. (2016) 200:171–6. doi: 10.1016/j.jss.2015.06.048
24. van der Stok EP, Spaander MCW, Grünhagen DJ, Verhoef G, Kuipers EJ. Surveillance after curative treatment for colorectal cancer. Nat Rev Clin Oncol. (2017) 14:297–315. doi: 10.1038/nrclinonc.2016.199
25. Sisic L, Strowitzki MJ, Blank S, Nienhaus H, Dorr S, Haag GM, et al. Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis. Gastric Cancer. (2018) 21:552–68. doi: 10.1007/s10120-017-0751-4
26. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Institute. (2008) 100:698–711. doi: 10.1093/jnci/djn134
27. Qu Z, Ling Q, Gwisda B, Xu X, Schrem H, Beneke J, et al. Hangzhou criteria are more accurate than Milan criteria in predicting long-term survival after liver transplantation for HCC in Germany. Langenbecks Arch Surg. (2018) 403:643–54. doi: 10.1007/s00423-018-1696-8
28. Ikegami T, Shimada M, Imura S, Yoshizumi T, Arakawa Y, Tokunaga T, et al. The timing of liver transplantation after primary
hepatectomy for hepatocellular carcinoma: a special reference to recurrence pattern and Milan criteria. Transplantation. (2008) 86:641–6. doi: 10.1097/TP.0b013e3181814de2

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.